# Insilico Medicine

Source: https://onco.cc/companies/insilico-medicine/  
OnCo record `insilico-medicine` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Generative-AI drug discovery company, listed in Hong Kong in December 2025, with a pan-KRAS candidate and a pan-TEAD inhibitor in the clinic.

## Summary

Insilico's 2025 listing was the largest Hong Kong biotech IPO of the year (HKD 2.28B). Pipeline of 31 nominated candidates with 13 IND clearances; oncology assets include ISM6166 (pan-KRAS) and ISM6331 (pan-TEAD, phase 1 data at ESMO 2026 in mesothelioma and solid tumours). Profitable in H1 2026 on licensing revenue.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Hong Kong / Boston
- Type: ai-software
- Website: https://insilico.com
- Ticker: 3696.HK

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Insilico_Medicine
- H1 2026 results: https://www.biospace.com/press-releases/commercialization-roadmap-validated-with-three-digit-million-dollar-revenue-insilico-medicine-announces-interim-results-for-the-first-half-of-2026

## Connected records

- cancers: [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [AI & Computation](https://onco.cc/fronts/ai-computation/), [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/)
- technologies: [AI-driven drug & target discovery](https://onco.cc/technologies/ai-drug-design/), [Chemistry42 and Pharma.AI (Insilico)](https://onco.cc/technologies/chemistry42/), [De novo designed protein binders](https://onco.cc/technologies/de-novo-protein-design/), [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- trials: [Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct06414460/), [Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors](https://onco.cc/trials/nct06566079/)
- bottlenecks: [The valley of death between lab and product](https://onco.cc/bottlenecks/b-translational-valley/)
- ideas: [A virtual cancer cell that predicts what a drug will do before you test it](https://onco.cc/ideas/idea-bio1-virtual-cell-perturbation/), [In silico trials to choose the dose before the first patient](https://onco.cc/ideas/idea-bio1-in-silico-trials-dose/)
- roadmaps: [AI in oncology roadmap: pattern readers → foundation models → agents in the workflow](https://onco.cc/roadmaps/ai-oncology-roadmap/), [Drug discovery roadmap: screening in mice → maps of dependency → designing in silico](https://onco.cc/roadmaps/drug-discovery-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/insilico-medicine.json